The October 20, 2026 deal gives Imunon equity, milestone payments up to $16.5 million, and royalties, while it keeps focus on its Phase 3 OVATION 3 trial.
SEC filing (5)
Arcus proposed a common stock offering through underwriters Jefferies, Leerink Partners and TD Cowen, pointing to casdatifan results and an estimated $694.0 million cash balance.
SEC filing (3)
The Hollister, California reagents maker filed a preliminary prospectus supplement dated October 20, 2026 for an undetermined number of shares, alongside early third-quarter revenue and margin estimates.
SEC filing (3)